Teva faces $100M lawsuit from Israel over unpaid Copaxone royalties: report

Teva Pharmaceuticals’ big-selling multiple sclerosis drug Copaxone is losing ground in the U.S. thanks to generics, but the medicine was once the company’s primary growth driver. Now, it’s at the center of a lawsuit filed by the state of Israel over alleged unpaid royalties.

Israel has sued Teva for $100 million in royalties on the longer-lasting version of the medicine, Globes reports. While Teva owns Copaxone marketing rights, scientists at the Weizmann Institute of Science developed the medicine, the publication reports. 

When the original daily version, first approved in the U.S. in 1996, neared its patent expiration, the company switched its efforts to a longer-acting version. In its lawsuit, Israel claims government scientists at the Weizmann Institute developed the long-acting version as well, so it’s owed royalties.

“The state has no alternative but to take legal action against Teva to ensure that it receives suitable remuneration for using public resources that brought Teva very large scale revenue,” the suit says, according to Globes. 

READ FULL